Sarepta Therapeutics, Inc. (SRPT) Reaches $100.59 After 5.00% Up Move; Caleres (CAL) Shorts Up By 11.57%

June 13, 2018 - By Vivian Currie

Caleres, Inc. (NYSE:CAL) Logo

The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a huge mover today! The stock increased 1.85% or $1.83 during the last trading session, reaching $100.59. About 696,720 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 13, 2017 and is uptrending. It has outperformed by 184.51% the S&P500. Some Historical SRPT News: ; 09/04/2018 – Merck’s Keytruda meets main goal in lung cancer trial; 30/04/2018 – Merck: FDA Grants Priority Review to sBLA for Keytruda Combination; 23/05/2018 – MERCK & CO INC – KEYTRUDA HAS NOW DEMONSTRATED AN IMPROVED SURVIVAL BENEFIT IN ADVANCED NSCLC IN FIVE PHASE 3 TRIALS; 06/04/2018 – Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma; 09/04/2018 – STAT Plus: With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies; 08/05/2018 – NEON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN CLINICAL TRIAL EVALUATING PERSONAL CANCER VACCINE NEO-PV-01 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) AND CHEMOTHERAPY; 16/04/2018 – BIOTHERA PHARMACEUTICALS PRESENTS TRANSLATIONAL DATA FROM ONGOING CLINICAL TRIALS SHOWING IMPRIME PGG IN COMBINATION WITH MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DRIVES INNATE AND ADAPTIVE IMMUNE…; 03/05/2018 – SAREPTA 1Q LOSS/SHR 55C; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients With Pegzilarginase in Both Monotherapy and KEYTRUDA Combination Trials; 15/03/2018 – Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 AmeriThe move comes after 8 months positive chart setup for the $6.59 billion company. It was reported on Jun, 13 by Barchart.com. We have $105.62 PT which if reached, will make NASDAQ:SRPT worth $329.60M more.

Caleres Inc (NYSE:CAL) had an increase of 11.57% in short interest. CAL’s SI was 1.49M shares in June as released by FINRA. Its up 11.57% from 1.34M shares previously. With 406,000 avg volume, 4 days are for Caleres Inc (NYSE:CAL)’s short sellers to cover CAL’s short positions. The SI to Caleres Inc’s float is 3.58%. The stock increased 0.49% or $0.17 during the last trading session, reaching $35.03. About 133,806 shares traded. Caleres, Inc. (NYSE:CAL) has risen 45.25% since June 13, 2017 and is uptrending. It has outperformed by 32.68% the S&P500. Some Historical CAL News: ; 13/03/2018 – Caleres 4Q Adj EPS 48c; 13/03/2018 – Caleres Sees 2018 Sales $2.8B; 13/03/2018 – Caleres Profit, Revenue Rise in Latest Quarter; 13/03/2018 – RPT-CALERES INC SEES 2018 FAMOUS FOOTWEAR SAME-STORE-SALES UP LOW-SINGLE DIGITS; 13/03/2018 – RPT-CALERES INC QTRLY FAMOUS FOOTWEAR TOTAL SALES OF $393.1 MLN WERE UP 7.0%; 06/03/2018 Caleres Closes Above 200-Day Moving Average: Technicals; 10/05/2018 – Caleres Names Molly Adams President of Famous Footwear; 13/03/2018 – CALERES INC QTRLY SAME-STORE-SALES WERE UP 2.8%; 20/04/2018 – DJ Caleres Inc, Inst Holders, 1Q 2018 (CAL); 13/03/2018 – CALERES SEES FY EPS $2.40 TO $2.50

Caleres, Inc., a footwear company, retails and wholesales footwear. The company has market cap of $1.51 billion. The firm operates through Famous Footwear and Brand Portfolio divisions. It has a 16.92 P/E ratio. It offers licensed, branded, and private-label casual, dress, and athletic footwear products to women, men, and children.

Among 12 analysts covering Caleres (NYSE:CAL), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. Caleres had 26 analyst reports since August 25, 2015 according to SRatingsIntel. As per Friday, December 4, the company rating was upgraded by Beaufort Securities. Loop Capital Markets initiated the stock with “Hold” rating in Thursday, June 7 report. The firm earned “Hold” rating on Wednesday, March 14 by Jefferies. The stock has “Outperform” rating by Wedbush on Wednesday, April 12. Susquehanna downgraded the stock to “Neutral” rating in Tuesday, January 23 report. The rating was upgraded by Buckingham Research on Thursday, February 25 to “Buy”. Wedbush maintained it with “Outperform” rating and $32 target in Thursday, November 23 report. The stock has “Speculative Buy” rating by Beaufort Securities on Wednesday, January 6. On Wednesday, December 7 the stock rating was upgraded by Susquehanna to “Positive”. BB&T Capital initiated the shares of CAL in report on Wednesday, January 27 with “Hold” rating.

More news for Caleres, Inc. (NYSE:CAL) were recently published by: Seekingalpha.com, which released: “Caleres, Inc. (CAL) CEO Diane Sullivan on Q1 2018 Results – Earnings Call Transcript” on June 01, 2018. Streetinsider.com‘s article titled: “After-Hours Stock Movers 05/31: (LULU) (AMBC) (VMW) Higher; (ONVO) (CAL) (ULTA) Lower (more…)” and published on May 31, 2018 is yet another important article.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.59 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 22 have Buy rating, 0 Sell and 5 Hold. Therefore 81% are positive. Sarepta Therapeutics had 120 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was upgraded by RBC Capital Markets to “Outperform” on Wednesday, August 26. The firm earned “Equal-Weight” rating on Wednesday, March 21 by Morgan Stanley. The firm has “Outperform” rating given on Tuesday, September 20 by Cowen & Co. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Outperform” rating given on Wednesday, April 6 by Oppenheimer. The rating was upgraded by Barclays Capital on Friday, May 11 to “Overweight”. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, June 21 report. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Overweight” rating by JP Morgan on Wednesday, February 21. The company was maintained on Thursday, August 27 by Robert W. Baird. Credit Suisse maintained the shares of SRPT in report on Friday, May 4 with “Outperform” rating. The firm has “Buy” rating given on Tuesday, September 12 by Cowen & Co.

Investors sentiment decreased to 0.97 in Q1 2018. Its down 0.25, from 1.22 in 2017Q4. It is negative, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported. Mufg Americas Corporation holds 0% or 220 shares. Tekla Capital Mgmt Limited Liability holds 1.09% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 378,516 shares. Alyeska Inv Group Limited Partnership owns 180,281 shares for 0.12% of their portfolio. 34,033 were reported by State Board Of Administration Of Florida Retirement System. Tiaa Cref Invest Ltd Liability Corporation stated it has 202,136 shares. Wexford Ltd Partnership reported 39,400 shares stake. Bluecrest Capital Management stated it has 4,409 shares. Balyasny Asset Mgmt Ltd Liability reported 0.13% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). J Goldman & Ltd Partnership invested in 43,767 shares. Moreover, Aperio Group Ltd Liability Corporation has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Dupont Cap Mgmt stated it has 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Blackrock Inc invested 0.02% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sphera Funds Mngmt Limited reported 248,997 shares stake. Lehman Financial Res stated it has 6,442 shares. 682,929 were accumulated by Goldman Sachs Grp Inc.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” on June 13, 2018, also Streetinsider.com with their article: “Sarepta Therapeutics (SRPT) Announces Long-term Strategic Manufacturing Partnership with Brammer Bio” published on June 13, 2018, Investorplace.com published: “7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.” on June 13, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: “EMA’s advisory committee thumbs down on Sarepta’s Exondys” published on June 01, 2018 as well as Bizjournals.com‘s news article titled: “Biogen’s head of late-stage trials leaves for Sarepta” with publication date: June 07, 2018.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on July, 18. They expect $-0.57 EPS, up 50.43% or $0.58 from last year’s $-1.15 per share. After $-0.44 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 29.55% negative EPS growth.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: